JP2009502951A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502951A5
JP2009502951A5 JP2008524162A JP2008524162A JP2009502951A5 JP 2009502951 A5 JP2009502951 A5 JP 2009502951A5 JP 2008524162 A JP2008524162 A JP 2008524162A JP 2008524162 A JP2008524162 A JP 2008524162A JP 2009502951 A5 JP2009502951 A5 JP 2009502951A5
Authority
JP
Japan
Prior art keywords
dosage form
guanfacine
weight
auc
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008524162A
Other languages
English (en)
Japanese (ja)
Other versions
JP5726401B2 (ja
JP2009502951A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/029277 external-priority patent/WO2007016284A2/en
Publication of JP2009502951A publication Critical patent/JP2009502951A/ja
Publication of JP2009502951A5 publication Critical patent/JP2009502951A5/ja
Application granted granted Critical
Publication of JP5726401B2 publication Critical patent/JP5726401B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008524162A 2005-07-28 2006-07-27 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形/組成物 Active JP5726401B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70298205P 2005-07-28 2005-07-28
US60/702,982 2005-07-28
PCT/US2006/029277 WO2007016284A2 (en) 2005-07-28 2006-07-27 Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012158337A Division JP2012229253A (ja) 2005-07-28 2012-07-17 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形/組成物

Publications (3)

Publication Number Publication Date
JP2009502951A JP2009502951A (ja) 2009-01-29
JP2009502951A5 true JP2009502951A5 (enExample) 2011-06-30
JP5726401B2 JP5726401B2 (ja) 2015-06-03

Family

ID=37668083

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008524162A Active JP5726401B2 (ja) 2005-07-28 2006-07-27 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形/組成物
JP2012158337A Pending JP2012229253A (ja) 2005-07-28 2012-07-17 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形/組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012158337A Pending JP2012229253A (ja) 2005-07-28 2012-07-17 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形/組成物

Country Status (18)

Country Link
US (1) US20070048371A1 (enExample)
EP (1) EP1909766B1 (enExample)
JP (2) JP5726401B2 (enExample)
KR (1) KR20080041669A (enExample)
CN (1) CN101252917A (enExample)
AR (1) AR054595A1 (enExample)
AU (1) AU2006275718B8 (enExample)
BR (1) BRPI0615989B8 (enExample)
CA (1) CA2616181C (enExample)
DK (1) DK1909766T3 (enExample)
ES (1) ES2566395T3 (enExample)
IL (1) IL188980A0 (enExample)
NO (1) NO20081038L (enExample)
NZ (1) NZ565649A (enExample)
RU (1) RU2435573C2 (enExample)
TW (1) TW200744672A (enExample)
WO (1) WO2007016284A2 (enExample)
ZA (1) ZA200801575B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916163D0 (en) * 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
HUE044221T2 (hu) * 2010-02-03 2019-10-28 Pharma Two B Ltd Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik
WO2011156710A2 (en) * 2010-06-11 2011-12-15 Shire Llc Combination therapy with lisdexamphetamine and extended release guanfacine
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
WO2014159340A1 (en) 2013-03-13 2014-10-02 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US10022341B2 (en) 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
JP6656670B2 (ja) * 2016-03-11 2020-03-04 国立大学法人 鹿児島大学 抗hcv活性を有する薬剤
EP4085907A1 (en) * 2016-04-20 2022-11-09 New Frontier Labs, LLC Diethyl azelate in the treatment of type 2 diabetes
WO2019136224A1 (en) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
JP2023035359A (ja) * 2021-09-01 2023-03-13 東和薬品株式会社 グアンファシン製剤
EP4292587A1 (en) 2022-06-15 2023-12-20 Sawai Pharmaceutical Co., Ltd. Guanfacine hydrochloride containing pharmaceutical preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649918A5 (de) * 1981-07-09 1985-06-28 Sandoz Ag Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
DE19834573A1 (de) * 1998-07-31 2000-02-03 Bayer Ag Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SI1355633T1 (en) * 2001-12-19 2005-06-30 Astrazeneca Ab NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2481236A1 (en) * 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
US6763509B2 (en) * 2002-09-26 2004-07-13 Sun Microsystems, Inc. Method and apparatus for allocating decoupling capacitor cells
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties

Similar Documents

Publication Publication Date Title
US9173857B2 (en) Controlled dose drug delivery system
AU2012230733B2 (en) Methods and compositions for treatment of attention deficit disorder
US20140099366A1 (en) Composition Containing Two Anti-Dementia Drugs
JP2009502951A5 (enExample)
US20100330150A1 (en) Orally Disintegrating Tablet Compositions Comprising Combinations of High and Low-Dose Drugs
ES2529455T3 (es) Sistema de administración de fármacos por dosis controladas
US20150087721A1 (en) Methods of administering amantadine
US9668993B2 (en) Non-steroidal anti-inflammatory drug dosing regimen
CN107205950A (zh) 金刚烷胺组合物的施用方法
WO2013001516A1 (en) Multilayered dosage form
US20070298098A1 (en) Controlled Release Compositions Comprising Levetiracetam
RU2008102911A (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
US20060246003A1 (en) Composition containing anti-dementia drug
US20050032879A1 (en) Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
AU2018320946A1 (en) Amantadine compositions, preparations thereof, and methods of use
HUE027498T2 (en) Pharmaceutical preparations containing trimetazidine
CA2746531C (en) Non-steroidal anti-inflammatory drug dosage form
WO2006088864A1 (en) Controlled release compositions comprising levetiracetam
CN121129799A (zh) 一种多重释放的缓控释组合物制剂及其制备方法和用途
CN102232934B (zh) 一种脉冲微丸及含其的脉冲口腔崩解片,制备方法和用途
CN119730840A (zh) 用于治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷
RU2006134695A (ru) Пероральная композиция с пролонгированным высвобождением молсидомина для лечения атеросклероза